<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00033306</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000069272</org_study_id>
    <secondary_id>UAB-0145</secondary_id>
    <secondary_id>BMS-CA163-012</secondary_id>
    <secondary_id>UAB-F011029021</secondary_id>
    <secondary_id>NCI-G02-2051</secondary_id>
    <nct_id>NCT00033306</nct_id>
  </id_info>
  <brief_title>BMS-247550 in Treating Patients With Metastatic Colorectal Cancer</brief_title>
  <official_title>A Phase II Study Of Epothilone Analog BMS-247550 In Patients With Metastatic Colorectal Cancer Previously Treated With A Fluoropyrimidine And Irinotecan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of BMS-247550 in treating patients who&#xD;
      have metastatic colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the clinical activity of BMS-247550, as measured by the tumor response rate,&#xD;
           in patients with metastatic colorectal cancer previously treated with a fluoropyrimidine&#xD;
           and irinotecan.&#xD;
&#xD;
        -  Determine the safety of this drug in these patients.&#xD;
&#xD;
        -  Determine the response duration, time to progression, and survival in patients treated&#xD;
           with this drug.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive BMS-247550 IV over 1 hour on days 1-5. Treatment repeats every 21 days for&#xD;
      up to 18 courses in the absence of disease progression or unacceptable toxicity. Patients&#xD;
      achieving a complete response (CR) receive up to 4 additional courses of treatment beyond CR.&#xD;
&#xD;
      Patients are followed every 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 19-55 patients will be accrued for this study within 6 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>February 2002</start_date>
  <completion_date type="Actual">July 2005</completion_date>
  <primary_completion_date type="Actual">July 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the clinical activity of BMS-247550, as measured by the tumor response rate, in patients with metastatic colorectal cancer previously treated with a fluoropyrimidine and irinotecan.</measure>
    <time_frame>baseline to survival</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the safety of this drug in these patients.</measure>
    <time_frame>baseline to survival</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the response duration, time to progression, and survival in patients treated with this drug.</measure>
    <time_frame>baseline to survival</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>BMS-247550</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ixabepilone</intervention_name>
    <arm_group_label>BMS-247550</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluoropyrimidine</intervention_name>
    <arm_group_label>BMS-247550</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <arm_group_label>BMS-247550</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed metastatic colorectal adenocarcinoma&#xD;
&#xD;
          -  Prior treatment for metastatic disease with at least:&#xD;
&#xD;
               -  One regimen of irinotecan in combination with a fluoropyrimidine OR&#xD;
&#xD;
               -  Two regimens comprising fluoropyrimidine-based first-line therapy and&#xD;
                  irinotecan-based second-line therapy&#xD;
&#xD;
                    -  May have received cetuximab and/or a fluoropyrimidine as part of second-&#xD;
                       line therapy&#xD;
&#xD;
          -  Disease progression during or within 4 months of treatment with irinotecan&#xD;
&#xD;
          -  At least 1 bidimensionally measurable lesion&#xD;
&#xD;
          -  No known CNS metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count at least 2,000/mm^3&#xD;
&#xD;
          -  Platelet count greater than 125,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  ALT no greater than 2.5 times ULN (5 times ULN if hepatic metastases present)&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times ULN&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No New York Heart Association class III or IV heart disease&#xD;
&#xD;
          -  No history of unstable angina, myocardial infarction, or congestive heart failure&#xD;
             within the past 6 months&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No known prior severe hypersensitivity reactions to agents containing Cremophor EL&#xD;
&#xD;
          -  No motor or sensory neuropathy grade 2 or greater&#xD;
&#xD;
          -  No concurrent serious uncontrolled infection or other nonmalignant medical illness&#xD;
&#xD;
          -  No concurrent psychiatric disorders or other conditions that would preclude study&#xD;
             compliance&#xD;
&#xD;
          -  No other active malignancy within the past 5 years except nonmelanoma skin cancer or&#xD;
             carcinoma in situ of the cervix&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
          -  No growth factors for 24 hours before and after cytotoxic chemotherapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Additional prior adjuvant or neoadjuvant chemotherapy allowed&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy and recovered&#xD;
&#xD;
          -  No more than 2 prior regimens of cytotoxic chemotherapy for metastatic disease&#xD;
&#xD;
          -  No prior oxaliplatin&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No concurrent hormonal therapy except hormone replacement therapy&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 3 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  No prior radiotherapy to target lesion unless the lesion has shown progression after&#xD;
             completion of radiotherapy&#xD;
&#xD;
          -  No concurrent therapeutic radiotherapy&#xD;
&#xD;
               -  Focal radiotherapy for palliation of bone symptoms may be allowed&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  At least 1 week since prior minor surgery (3 weeks for major surgery) and recovered&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other concurrent experimental anticancer medications&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andres Forero-Torres, MD, CSU</last_name>
    <role>Study Chair</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham Comprehensive Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-3300</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgia Cancer Specialists</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <study_first_submitted>April 9, 2002</study_first_submitted>
  <study_first_submitted_qc>August 5, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2003</study_first_posted>
  <last_update_submitted>August 1, 2013</last_update_submitted>
  <last_update_submitted_qc>August 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV colon cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <keyword>adenocarcinoma of the colon</keyword>
  <keyword>adenocarcinoma of the rectum</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

